Carcinoma, Renal Cell: all 1,992 studies
Page 18 of 20. Open to participants first (387), then studies with results posted, then the rest; newest registration first within each.
- MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney CancerStatus unknownNCT00873236Phase 2
- Study In Patients With Kidney Cancer Treated With SutentCompletedNCT00873210
- Exercise for Patients With Renal Cell Cancer Receiving SunitinibStatus unknownNCT00869011Phase 3
- DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell CarcinomaStatus unknownNCT00862303Phase 1/2
- VEG111485: A QTc Study of PazopanibCompletedNCT00861029Phase 1
- Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid TumorsCompletedNCT00855452Phase 2
- Genetic Susceptibility to Kidney CancerTerminatedNCT00854022
- Study of Sorafenib in Patients With Advanced Renal Cell CarcinomaCompletedNCT00848640Phase 2
- Impact of Predicting Anti-angiogenic Response in mRCC Using Functional ImagingCompletedNCT00842790
- VEGF Imaging in Renal Cell CarcinomaCompletedNCT00831857
- RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)CompletedNCT00830895Phase 2
- A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell CancerTerminatedNCT00816686Phase 1
- Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the BrainCompletedNCT00814021Phase 2
- Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney CancerCompletedNCT00806650
- A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell CarcinomaCompletedNCT00788060Phase 1
- Study to the Optimal Duration of Therapy With Oral Angiogenesis InhibitorsStatus unknownNCT00777504Phase 4
- A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®CompletedNCT00771147
- Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)CompletedNCT00749320Not applicable
- Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By SurgeryTerminatedNCT00747305Phase 1
- Warm Ischemia or Cold Ischemia During Surgery in Treating Patients With Stage I Kidney CancerCompletedNCT00743236Not applicable
- microRNA Expression in Renal Cell CarcinomaCompletedNCT00743054
- A Phase II Study of AS1411 in Renal Cell CarcinomaStatus unknownNCT00740441Phase 2
- Sequential Study to Treat Renal Cell CarcinomaCompletedNCT00732914Phase 3
- Correlation of the Clinical Behaviour of Renal Cell Carcinoma (RCC) After Debulking Nephrectomy With Tumor Gene Expression in Nephrectomy SpecimensCompletedNCT00718367
- T Regulatory Cells in Renal Cell Carcinoma (PILOT STUDY)CompletedNCT00717743
- Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney CancerStatus unknownNCT00717587Phase 2
- Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)Active, not recruitingNCT00715442Phase 2
- A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell CancerCompletedNCT00715182Phase 1
- Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma TreatmentCompletedNCT00678119Phase 2
- Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous NefrectomyCompletedNCT00663559Phase 2
- BAY43-9006 Phase II Study for Renal Cell CarcinomaCompletedNCT00661375Phase 2
- Follow-Up Study of Kidney Cancer PatientsCompletedNCT00656955
- Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.CompletedNCT00656734Phase 1
- Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsCompletedNCT00655655Phase 1
- Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor TherapyNo longer availableNCT00655252
- Phase I Study of Vorinostat and Sorafenib in Advanced CancerCompletedNCT00635791Phase 1
- Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney CancerStatus unknownNCT00626509Phase 2
- Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant MelanomaCompletedNCT00625768Phase 1
- A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell CarcinomaCompletedNCT00625755Phase 1/2
- Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid TumorsCompletedNCT00625456Phase 1
- Bortezomib and Cetuximab in Treating Patients With Advanced Solid TumorsCompletedNCT00622674Phase 1
- Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.TerminatedNCT00622479Phase 1
- Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid TumorsCompletedNCT00620295Phase 1
- Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell CarcinomaCompletedNCT00619268Phase 2
- Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic MelanomaCompletedNCT00617799
- Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma PatientsCompletedNCT00617253Phase 2
- Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid TumorsStatus unknownNCT00610389Phase 2
- Tumor Registry of Advanced Renal Cell CarcinomaCompletedNCT00610012
- Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the BoneCompletedNCT00609934Phase 1/2
- Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)CompletedNCT00609401Phase 2
- MRI Study of BAY 43-9006 in Metastatic Renal Cell CarcinomaCompletedNCT00606866Phase 3
- Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250CompletedNCT00602862Not applicable
- RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell CarcinomaWithdrawnNCT00601120Not applicable
- Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based RegimensCompletedNCT00591188Phase 2
- Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung MetastasesCompletedNCT00588913Phase 1/2
- Treatment of Advanced Renal Cell Carcinoma With QuinacrineWithdrawnNCT00574483Phase 2
- Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)CompletedNCT00570882Phase 2
- A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell CarcinomaCompletedNCT00563147Phase 1
- Phase 2 Study in Patients With MiT TumorsCompletedNCT00557609Phase 2
- Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell CarcinomaWithdrawnNCT00556205Phase 2
- Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell CancerCompletedNCT00541008Phase 2
- An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed After Sunitinib TherapyWithdrawnNCT00538772
- A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248CompletedNCT00531544Not applicable
- IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable DiseaseCompletedNCT00523159Phase 2
- Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCCTerminatedNCT00522249Phase 1/2
- Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid TumorsCompletedNCT00516672Phase 1
- Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic AnemiaCompletedNCT00513175
- Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell CarcinomaCompletedNCT00509704
- Biobehavioral Effects of Emotional Expression in CancerCompletedNCT00505310Not applicable
- Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.CompletedNCT00502034Phase 3
- Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial CancerTerminatedNCT00499733Early Phase 1
- Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid TumorsCompletedNCT00499135Phase 1
- Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCCCompletedNCT00496301Phase 2
- An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell CarcinomaCompletedNCT00492986Phase 3
- Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney CancerTerminatedNCT00492440Phase 1
- Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney CancerCompletedNCT00492258Phase 3
- Talabostat in Treating Patients With Metastatic Kidney CancerWithdrawnNCT00489710Phase 2
- Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With SunitinibCompletedNCT00486538Phase 2
- A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell CarcinomaTerminatedNCT00485563Phase 2
- A Study of Neoadjuvant Sutent for Patients With Renal Cell CarcinomaTerminatedNCT00480935Phase 2
- Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney RemovalCompletedNCT00480389Phase 2
- Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034CompletedNCT00478725Phase 1
- Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)CompletedNCT00478114Phase 3
- AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With SorafenibCompletedNCT00467025Phase 2
- A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal CancerCompletedNCT00448721Phase 2
- Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney CancerCompletedNCT00448149Phase 1/2
- Safety Study of RAD001 to Treat Patients With Metastatic Kidney CancerCompletedNCT00446368Phase 2
- Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal CancerCompletedNCT00445523Phase 2
- Safety and Toxicity Study of Sorafenib in Patients With Kidney CancerCompletedNCT00445042Phase 2
- Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell CarcinomaCompletedNCT00444314Phase 2
- Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney CancerTerminatedNCT00440973Phase 2
- Study for Patients Who Have Benefited and Tolerated Prior Panitumumab TreatmentCompletedNCT00425204Phase 2
- Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2CompletedNCT00425035Phase 2
- Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell CarcinomaCompletedNCT00422786Phase 2
- A Study of RAD001 and Sunitinib in Metastatic Renal Cell CarcinomaCompletedNCT00422344Phase 1
- A Phase II Study to Treat Subjects With Advanced Renal Cell CarcinomaCompletedNCT00422019Phase 2
- A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma PatientsCompletedNCT00421512Phase 1
- ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell CarcinomaCompletedNCT00420888Phase 2/3
- Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic MelanomaCompletedNCT00418496Phase 1
- A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell CarcinomaTerminatedNCT00417677Phase 1/2